April 1, 2013 — Invivo and iCAD Inc. announced the companies have entered into a global research, development and commercial agreement.
Under the agreement, iCAD will develop advanced magnetic resonance imaging (MRI) analysis software products, which Invivo will incorporate into its suite of MRI product solutions for global commercial sale. The first products are anticipated to be available between April and June of 2013. The initial focus of the partnership will be the release of a next generation platform for prostate and breast imaging. Additional new product releases are also anticipated beginning the second half of 2013.
This agreement allows iCAD and Invivo to continue bringing customers a suite of MR products including coils, accessories, and software.
“The collaboration with Invivo combines the strengths of two market leaders with synergistic technologies that will provide more robust product innovations, allowing us to further deliver on our mission to offer comprehensive imaging solutions that aid in the detection and treatment of cancer,” said Ken Ferry, CEO of iCAD.
“iCAD’s MRI advanced image analysis products and technologies are a strong complement to Invivo’s market-leading breast and prostate clinical solutions,” said Brent Berthy, general manager of Invivo.
The DynaCAD 3.0 platform offers a feature-rich workspace allowing the user to manage data, generate analysis reports and communicate results in a single solution. The qualitative and quantitative image analysis tools improve workflow efficiency and provide improved flexibility for radiologists to quickly determine areas of concern for further assessment.
For more information: www.invivocorp.com, www.icadmed.com
June 18, 2026 
